🇺🇸 FDA
Pipeline program

XEN1101

XPF-010-303

Phase 3 small_molecule active

Quick answer

XEN1101 for Primary Generalized Tonic-Clonic Seizures is a Phase 3 program (small_molecule) at Xenon Pharmaceuticals with 1 ClinicalTrials.gov record(s).

Program details

Company
Xenon Pharmaceuticals
Indication
Primary Generalized Tonic-Clonic Seizures
Phase
Phase 3
Modality
small_molecule
Status
active

Clinical trials